Y0000341
Loperamide oxide monohydrate
European Pharmacopoeia (EP) Reference Standard
동의어(들):
trans-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-oxide monohydrate
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
20 MG
₩212,541
About This Item
실험식(Hill 표기법):
C29H33ClN2O3 · H2O
CAS Number:
Molecular Weight:
511.05
UNSPSC 코드:
41116107
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
loperamide
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
Clc1ccc(cc1)C2(CC[N](=O)(CC2)CCC(c4ccccc4)(c3ccccc3)C(=O)N(C)C)O
InChI
1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
InChI key
KXVSBTJVTUVNPM-UHFFFAOYSA-N
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Loperamide oxide monohydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Oral
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
L E Van Beijsterveldt et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(2), 216-222 (1995-02-01)
Loperamide oxide is a prodrug of the effective antidiarrheal loperamide. Administration of this prodrug improves efficacy and tolerability. For better understanding of these effects, the absorption and gastrointestinal distribution of loperamide oxide and of its active drug loperamide were studied.
Treatment of irritable bowel syndrome with loperamide oxide. An open study to determine optimal dosage.
G Ragnarsson et al.
Journal of internal medicine, 248(2), 165-166 (2000-08-18)
K Lavrijsen et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(3), 354-362 (1995-03-01)
Loperamide oxide (LOPOX) is a prodrug of loperamide (LOP). The reduction of LOPOX to LOP was investigated to provide a pharmacokinetic basis for the pharmacodynamics and improved side effect profile of the prodrug. Reduction of LOPOX was studied in vitro
M van Outryve et al.
The Journal of international medical research, 23(5), 335-341 (1995-09-01)
Loperamide oxide was compared with placebo for the treatment of chronic diarrhoea in patients with Crohn's disease. After initially receiving 2 mg loperamide oxide or placebo, hospital out-patients with Crohn's disease were instructed to take one tablet of loperamide oxide
F Kamali et al.
European journal of clinical pharmacology, 42(6), 693-694 (1992-01-01)
The pharmacokinetics of loperamide, after oral administration of increasing doses (1 to 16 mg) of loperamide oxide, has been investigated in 10 healthy male volunteers, using a randomised cross-over design. Comparison of the maximum plasma loperamide concentration and AUC demonstrated
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
